Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib in ALK+ NSCLC Post-Crizotinib
NCT01801111Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2013
- Primary completion
- Oct 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 16
01
Overview
Phase 2, open-label, single-arm trial of alectinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoints: Recommended Phase 2 Dose, Percentage of Participants With Dose Limiting Toxicities and 1 more. Started Jun 2013; status: completed.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01801111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01801111.